COSCIENS Biopharma Reports Q3 2025 Financial Results
I'm PortAI, I can summarize articles.
Cosciens Biopharma Inc. (CSCIF) reported its Q3 2025 financial results, showing a consolidated net loss of $1.8 million, an improvement from $5.8 million in Q3 2024. The company has delisted from Nasdaq but remains on the Toronto Stock Exchange. Total revenue decreased to $1.5 million, down from $1.9 million, due to reduced sales. Strategic initiatives include suspending the Juvente Cosmeceuticals line and focusing on expanding active ingredients into new markets. COSCIENS aims to enhance operational efficiency and explore partnerships in the U.S. market.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments